<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470405</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PHI0367</org_study_id>
    <secondary_id>VU-VICC-PHI-0367</secondary_id>
    <secondary_id>LILLY-H3E-US-S053A</secondary_id>
    <secondary_id>VU-IRB-031027</secondary_id>
    <nct_id>NCT00470405</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. Giving pemetrexed together with oxaliplatin may kill more cancer cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed given
      together with oxaliplatin in treating patients with metastatic solid tumors or lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose and the recommended phase II dose of pemetrexed
           disodium in combination with oxaliplatin in patients with metastatic solid tumors or
           lymphoma.

      Secondary

        -  Determine the quantitative and qualitative toxicities of this regimen in these patients.

        -  Determine, preliminarily, the efficacy of this regimen in these patients.

      OUTLINE: This is a dose-escalation study.

      Patients receive pemetrexed disodium IV over 10 minutes and oxaliplatin IV over 2 hours on
      day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable
      toxicity.

      Cohorts of 3-6 patients receive escalating doses of pemetrexed disodium and oxaliplatin until
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is
      determined, the recommended phase II dose will be identified.

      After completion of study treatment, patients are followed at 30 days and then periodically
      thereafter.

      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>Elaxtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>a novel antifolate with multiple targets.</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic or cytologic diagnosis of solid tumors or lymphoma

          -  Metastatic disease

               -  No curative or effective therapy exists

          -  Measurable or nonmeasurable disease

          -  No clinically relevant third-space fluid collections

               -  Fluid collections must be drained before study enrollment

          -  No leukemia

          -  No CNS metastases

        Exclusion Criteria:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)

          -  Creatinine clearance ≥ 45 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study therapy

          -  No active infection or other serious illness that would preclude study participation

          -  No weight loss ≥ 10% within the past 6 weeks

          -  No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1

          -  Must be able to take concurrent vitamin B12 and folic acid

        PRIOR CONCURRENT THERAPY:

          -  No more than 1 prior chemotherapy regimen for metastatic disease

          -  More than 12 months since prior adjuvant therapy

          -  More than 30 days since prior drug that has not received regulatory approval

          -  More than 30 days since prior radiation therapy and recovered (alopecia allowed)

          -  Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed

          -  No prior radiation therapy to ≥ 25% of bone marrow

          -  No prior oxaliplatin or pemetrexed disodium

          -  No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents [e.g.,
             piroxicam]), during, and for 2 days after each dose of pemetrexed disodium

          -  No concurrent nonpalliative radiation therapy or surgery for cancer

          -  No concurrent hormonal cancer therapy (except medroxyprogesterone)

          -  No other concurrent experimental medications (except thymidine)

          -  No other concurrent chemotherapy or immunotherapy

          -  No other concurrent anticancer therapy

          -  Concurrent palliative radiation therapy allowed for small areas of painful metastasis
             that cannot be managed adequately by systemic or local analgesics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mace L. Rothenberg, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs. 2008 Aug;26(4):339-45. doi: 10.1007/s10637-008-9133-4. Epub 2008 May 8.</citation>
    <PMID>18463792</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mace Rothenberg</name_title>
    <organization>Vanderbilt-Ingram Cancer Center</organization>
  </responsible_party>
  <keyword>adult solid tumor</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

